NICHOLAS GALAKATOS
CIK 1252522 · last filed 2019-06-21
NICHOLAS GALAKATOS is a corporate insider who has filed 59 SEC Form 4 insider transactions across 21 companies since 2007. The most recent filing, for ETTX, was dated Jun 21, 2019. Across all open-market trades the lifetime net is −$11.3M, making them a net seller over the disclosed history. 152 SEC filings were submitted jointly with MICHAEL STEINMETZ.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
21
Total Filings
59
Lifetime Open-Market Net
-$11.27M
Filer Profile
Reported Address
THE JOHN HANCOCK TOWER200 CLARENDON STREET, 54TH FLOOR
BOSTON, MA 02116
Related Filers
MICHAEL STEINMETZ — 152 joint filings, latest 2016-02-10
KURT WHEELER — 152 joint filings, latest 2018-07-02
DENNIS HENNER — 106 joint filings, latest 2018-07-02
ANSBERT GADICKE — 80 joint filings, latest 2013-02-07
LUKE EVNIN — 65 joint filings, latest 2013-02-07
ROBERT LIPTAK — 56 joint filings, latest 2018-07-02
Nicholas Simon — 54 joint filings, latest 2018-07-02
Clarus Lifesciences II, L.P. — 32 joint filings, latest 2017-10-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Director | 1,170,010 | $2.19 | $2.56M | $6.80M | 3 | 2019-06-21 |
| NanoString Technologies Inc (NSTG) Delisted | Director | 4,036,025 | $0.11 | $425.0K | -$1.37M | 9 | 2019-03-27 |
| Forty Seven, Inc. (FTSV) Delisted | 10%+ Owner | 938,489 | — | — | $28.80M | 1 | 2018-07-02 |
| Astria Therapeutics, Inc. (CATB) Delisted | Director | 395,966 | $8.54 | $3.38M | $4.52M | 2 | 2016-08-05 |
| TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted | 10%+ Owner | 4,332,775 | — | — | -$773.8K | 1 | 2016-01-28 |
| IVERIC bio, Inc. (OPHT) Delisted | Director | 11,129 | — | — | -$629.5K | 11 | 2016-01-13 |
| Oxford Immunotec Global PLC (OXFD) Delisted | 10%+ Owner | 2,334,854 | — | — | -$4.17M | 1 | 2015-06-03 |
| AERIE PHARMACEUTICALS INC (AERI) Delisted | 10%+ Owner | 3,468,494 | $15.25 | $52.89M | $28.89M | 1 | 2015-01-30 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 31,651 | — | — | $0 | 4 | 2014-07-01 |
| Pernix Sleep, Inc. (SOMX) Delisted | 10%+ Owner | 472,717 | — | — | $63.7K | 3 | 2012-06-19 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Director | 220,896 | $15.00 | $3.31M | $0 | 3 | 2011-06-03 |
| AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted | 10%+ Owner | 8,246,414 | — | — | -$71.37M | 1 | 2010-11-05 |
| SENORX INC (SENO) Delisted | 10%+ Owner | 2,032,475 | — | — | -$22.81M | 1 | 2010-06-29 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 10%+ Owner | 14,633,961 | — | — | $0 | 1 | 2010-01-04 |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | 10%+ Owner | 4,942,067 | — | — | -$10.49M | 1 | 2009-12-23 |
| AFFYMAX INC (AFFY) Delisted | Director | — | — | — | $0 | 3 | 2009-05-29 |
| Pharmasset Inc (VRUS) Delisted | 10%+ Owner | 5,199 | — | — | -$1.43M | 2 | 2008-02-22 |
| Altimmune, Inc. (HAQ.WS) Delisted | 10%+ Owner | 3,468,250 | — | — | $6.74M | 1 | 2007-08-07 |
| HELICOS BIOSCIENCES CORP (HLCS) Delisted | 10%+ Owner | 2,987,769 | — | — | $21.00M | 1 | 2007-05-31 |
| CRYOCOR INC (CRYO) Delisted | 10%+ Owner | 3,028,082 | — | — | $4.96M | 1 | 2007-04-25 |
| CORNERSTONE THERAPEUTICS INC (CRTX) Delisted | Director | 963 | $1.95 | $1.9K | $0 | 2 | 2007-02-15 |
Recent Filings
59 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-06-21 | Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-03-27 | NanoString Technologies Inc (NSTG) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-01-22 | Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-10-02 | Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Mixed | +1,551,148 | $6.80M | EDGAR |
| 2018-09-19 | NanoString Technologies Inc (NSTG) Delisted | Mixed | +76,585 | -$287 | EDGAR |
| 2018-07-02 | Forty Seven, Inc. (FTSV) Delisted | Mixed | +34,352,559 | $28.80M | EDGAR |
| 2018-01-03 | NanoString Technologies Inc (NSTG) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-01-04 | NanoString Technologies Inc (NSTG) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-08-05 | Astria Therapeutics, Inc. (CATB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-01-28 | TETRALOGIC PHARMACEUTICALS CORP (TLOG) Delisted | Sell (S) | −2,807,370 | -$773.8K | EDGAR |
Showing 1–10 of 59
Page 1 of 6
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.